Development of de novo cancer in p53 knock-out mice is dependent on the type of long-term immunosuppression used

Transplantation

Volumn 82, Issue 6, 2006, Pages 741-748

  Koehl, Gudrun E ^a   Gaumann, Andreas ^a   Zuelke, Carl ^a   Hoehn, Anna ^a   Hofstaedter, Ferdinand ^a   Schlitt, Hans J ^a   Geissler, Edward K ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cyclosporine; De novo cancer; Mycophenolate mofetil; p53; Rapamycin

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEIN P53; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; GENE MUTATION; HISTOLOGY; IMMUNOSUPPRESSIVE TREATMENT; KNOCKOUT MOUSE; LONG TERM CARE; LYMPHOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; STATISTICAL ANALYSIS;

ANIMALS; ANTICARCINOGENIC AGENTS; CYCLOSPORINE; DISEASE-FREE SURVIVAL; GENES, P53; IMMUNOSUPPRESSIVE AGENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYCOPHENOLIC ACID; NEOPLASMS, EXPERIMENTAL; SIROLIMUS;

EID: 33749127216     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000233852.75162.74     Document Type: Article

References (31)

1. Buell J, Hanaway M, Thomas M. Malignancies associated with liver transplantation. In: Busuttil RW, Klintmalm GB, eds. Transplantation of the liver. Philadelphia: WB Saunders, 2004.
2. Buell J, Gross T, Beebe T. Cancer after renal transplantation. In: Cohen EP, ed. Cancer and the kidney. New York: Oxford University Press, 2004.
3. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005; 80: S254.
4. McDonald S, Excell L, Livingston B. Deaths: ANZDATA Registry 2005 report, 2005: 45-53.
5. Yao FY, Ferrell L, Bass NM, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001; 33: 1394.
6. Jain A, DiMartini A, Kashyap R, et al. Long-term follow-up after liver transplantation for alcoholic liver disease under tacrolimus. Transplantation 2000; 70: 1335.
7. Gallo P, Agozzino L, Angelini A, et al. Causes of late failure after heart transplantation: a ten-year survey. J Heart Lung Transpl 1997; 16: 1113.
8. Sheil AG, Disney AP, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc 1993; 25: 1383.
9. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8: 128.
10. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002; 73: 1565.
11. s6K pathway in human pancreatic cancer cells. Cancer Res 1999; 59: 3581.
12. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005; 120: 747.
13. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999; 397: 530.
14. Herman M, Weinstein T, Korzets A, et al. Effect of cyclosporin A on DNA repair and cancer incidence in kidney transplant recipients. J Lab Clin Med 2001; 137: 14.
15. Koehl G, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319.
16. Robson R, Cecka JM, Opelz G, et al. Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil. Am J Transplant 2005; 5: 2954.
17. Hussein MM, Mooij JM, Roujouleh HM. Regression of post-transplant Kaposi sarcoma after discontinuing cyclosporin and giving mycophenolate mofetil instead. Nephrol Dial Transpl 2000; 15: 1103.
18. Carter SB, Franklin TJ, Jones DF, et al. Mycophenolic acid: an anticancer compound with unusual properties. Nature 1969; 223: 848.
19. Suzuki S, Kimura T, Ando K, et al. Antitumor activity of mycophenolic acid. J Antibiot 1969; 22: 297.
20. Engl T, Makarevic J, Relja B, et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005; 5: 4.
21. Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transplant 1998; 147: 158.
22. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992; 356: 215.
23. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107.
24. Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63: 917.
25. Bruns CJ, Koehl G, Guba M, et al. Rapamycin-induced endothelial cell death and tumor-vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 2004; 10: 2109.
26. 1 arrest and determine the cellular response to rapamycin. Cancer Res 2001; 61: 3373.
27. van Kranen HJ, Westerman A, Berg RJ, et al. Dose-dependent effects of UVB-induced skin carcinogenesis in hairless p53 knockout mice. Mutat Res 2005; 571: 81.
28. Rebel H, Kram N, Westerman A, et al. Relationship between UV-induced mutant p53 patches and skin tumours, analysed by mutation spectra and by induction kinetics in various DNA-repair-deficient mice. Carcinogenesis 2005; 26: 2123.
29. Maluccio M, Sharma V, Lagman M, et al. Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. Transplantation 2003; 76: 597.
30. Dantal J, Hourmant M, Cantarovich D, et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
31. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883.